| 1 |
34342264 | Oxaliplatin resistance in colorectal cancer enhances TRAIL sensitivity via death receptor 4 upregulation and lipid raft localization. | 2021 Aug 3 |
2 |
| 2 |
26377238 | Oxaliplatin immuno hybrid nanoparticles for active targeting: an approach for enhanced apoptotic activity and drug delivery to colorectal tumors. | 2016 Jun |
1 |
| 3 |
26697734 | Formulation and optimization of oxaliplatin immuno-nanoparticles using Box-Behnken design and cytotoxicity assessment for synergistic and receptor-mediated targeting in the treatment of colorectal cancer. | 2016 Dec |
1 |
| 4 |
23525071 | Induction of pancreatic cancer cell apoptosis, invasion, migration, and enhancement of chemotherapy sensitivity of gemcitabine, 5-FU, and oxaliplatin by hnRNP A2/B1 siRNA. | 2013 Jul |
1 |
| 5 |
22994781 | Oxaliplatin sensitizes OS cells to TRAIL-induced apoptosis via down-regulation of Mcl1. | 2012 |
3 |
| 6 |
21683075 | Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL. | 2011 Aug |
10 |
| 7 |
21699898 | Oxaliplatin uses JNK to restore TRAIL sensitivity in cancer cells through Bcl-xL inactivation. | 2011 Aug |
1 |
| 8 |
19223002 | Oxaliplatin enhances TRAIL-induced apoptosis in gastric cancer cells by CBL-regulated death receptor redistribution in lipid rafts. | 2009 Mar 4 |
3 |
| 9 |
18345033 | P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells. | 2008 Jul 10 |
4 |
| 10 |
16638878 | Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. | 2006 Apr 15 |
1 |
| 11 |
17097066 | Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK activation. | 2006 Dec 29 |
1 |